Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700954 | 0.77 | HTT (0.52) | GRIA1GRIA2GRIA3GRIA4HTT | |
| SCHEMBL12343345 | 0.77 | PTGS2 (0.47) | TSHRHTTALDH1A1PTGS2 | |
| SCHEMBL21728685 | 0.76 | KDM4E (0.45) | KDM4E | |
| SCHEMBL14154659 | 0.75 | MEN1 (0.45) | GRIA1GRIA2GRIA3GRIA4HTT | |
| SCHEMBL2938277 | 0.75 | PTGS2 (0.35) | GRIA1GRIA2GRIA3GRIA4HTT | |
| SCHEMBL22044444 | 0.73 | NPC1 (0.34) | GRIA1GRIA2GRIA3GRIA4PTGS2 | |
| SCHEMBL18179861 | 0.72 | BAZ2B (0.46) | TSHRHTTALDH1A1KDM4EPTGS2 | |
| SCHEMBL17452649 | 0.71 | HTT (0.71) | HTTALDH1A1KDM4EPTGS2GAA | |
| SCHEMBL24872432 | 0.69 | NPC1 (0.34) | GRIA1GRIA2GRIA3GRIA4PTGS2 | |
| SCHEMBL1412553 | 0.69 | TP53 (0.56) | TSHRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | RECQL, DDX21, DDX41 | GRIA1 4298/4885GRIA2 4245/4885GRIA3 4403/4885 |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | GRIA1 4718/4885GRIA2 4859/4885GRIA3 4670/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | GRIA1 4681/4885GRIA2 4814/4885GRIA3 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.